https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Epigenetic mechanisms and therapeutic targets in chemoresistant high-grade serous ovarian cancer https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:48589 Wed 22 Mar 2023 08:32:47 AEDT ]]> Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:27356  G variant (rs152451) was significantly enriched in cases and may represent a low-penetrance polymorphism (p = 0.002; OR 1.24 (95 % CI 1.09–1.47). Conclusions: Our findings support truncating variants in PALB2 as high-penetrance breast cancer susceptibility alleles, and suggest that a common missense variant may also lead to a low level of increased breast cancer risk.]]> Wed 11 Apr 2018 17:01:50 AEST ]]> Reevaluation of the BRCA<sub>2</sub> truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer context https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:22707 BRCA2, has a large number of genetic variants of unknown effect. The variant rs11571833, an A > T transversion in the final exon of the gene that leads to the creation of a stop codon 93 amino acids early (K3326*), is reported as a neutral polymorphism but there is some evidence to suggest an association with an increased risk of breast cancer. We assessed whether this variant was enriched in a cohort of breast cancer cases ascertained through familial cancer clinics compared to population-based non-cancer controls using a targeted sequencing approach. We identified the variant in 66/2634 (2.5%) cases and 33/1996 (1.65%) controls, indicating an enrichment in the breast cancer cases (p = 0.047, OR 1.53, 95% CI 1.00–2.34). This data is consistent with recent iCOGs data suggesting that this variant is not neutral with respect to breast cancer risk. rs11571833 may need to be included in SNP panels for evaluating breast cancer risk.]]> Wed 11 Apr 2018 09:55:17 AEST ]]> BCL-2 family isoforms in apoptosis and cancer https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:36748 Wed 10 Nov 2021 15:04:41 AEDT ]]> Panel testing for familial breast cancer: calibrating the tension between research and clinical care https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:24890 Wed 09 Feb 2022 15:54:09 AEDT ]]> Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:27801 Wed 04 Apr 2018 17:04:59 AEST ]]> Reevaluation of RINT1 as a breast cancer predisposition gene https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:23843 0.999) or in the number of variants predicted to be pathogenic by various in silico tools (Condel, Polyphen2, SIFT, and CADD) in the cases compared to the controls. In addition, there was no difference in the incidence of classic Lynch syndrome cancers in RINT1 rare variant-carrying families compared to RINT1 wild-type families. This study had 90 % power to detect an odds ratio of at least 2.06, and the results do not provide any support for RINT1 being a moderate-penetrance breast cancer susceptibility gene, although larger studies will be required to exclude more modest effects. This study emphasizes the need for caution before designating a cancer predisposition role for any gene based on very rare truncating variants and in silico-predicted missense variants.]]> Wed 02 Mar 2022 14:25:02 AEDT ]]> Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:48290 Tue 14 Mar 2023 11:54:53 AEDT ]]> Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:45361 BRCA1 and BRCA2, including the identification of new predisposing genes. A total of 11,511 non-BRCA familial BC cases and population-matched cancer-free female controls in the BEACCON study were investigated in two sequencing phases: 1303 candidate genes in up to 3892 cases and controls, followed by validation of 145 shortlisted genes in an additional 7619 subjects. The coding regions and exon–intron boundaries of all candidate genes and 14 previously proposed BC genes were sequenced using custom designed sequencing panels. Pedigree and pathology data were analysed to identify genotype-specific associations. The contribution of ATM, PALB2 and CHEK2 to BC predisposition was confirmed, but not RAD50 and NBN. An overall excess of loss-of-function (LoF) (OR 1.27, p = 9.05 × 10−9) and missense (OR 1.27, p = 3.96 × 10−73) variants was observed in the cases for the 145 candidate genes. Leading candidates harbored LoF variants with observed ORs of 2–4 and individually accounted for no more than 0.79% of the cases. New genes proposed by this study include NTHL1, WRN, PARP2, CTH and CDK9. The new candidate BC predisposition genes identified in BEACCON indicate that much of the remaining genetic causes of high-risk BC families are due to genes in which pathogenic variants are both very rare and convey only low to moderate risk.]]> Thu 27 Oct 2022 15:32:46 AEDT ]]> The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:18919 Sat 24 Mar 2018 07:59:01 AEDT ]]> Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:19125 C) were found. In addition, five variants predicted to be protein-affecting were also identified. Our study shows that the prevalence of PALB2 germline mutations in individuals with TNBC is ~1%, similar to the prevalence of PALB2 germline mutation of 1% in familial non-BRCA1/2 breast cancer cohorts.]]> Sat 24 Mar 2018 07:55:57 AEDT ]]> The presence of the intron 3 16 bp duplication polymorphism of p53 (rs17878362) in breast cancer is associated with a low ∆40p53:p53 ratio and better outcome https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:24332 Sat 24 Mar 2018 07:16:38 AEDT ]]> Methyl-donor and cofactor nutrient intakes in the first 2-3 years and global DNA methylation at age 4: a prospective cohort study https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:32077 0.05). Global DNA methylation levels in males were significantly higher than in females (median %5-mC: 1.82 vs. 1.03, males and females respectively, (P < 0.05)). Conclusion: No association was found between the intake of one-carbon metabolism nutrients during the early postnatal period and global DNA methylation levels at age four years. Higher global DNA methylation levels in males warrants further investigation.]]> Mon 23 Sep 2019 11:18:49 AEST ]]> Global DNA methylation and cognitive and behavioral outcomes at 4 years of age: a cross-sectional study https://novaprd-lb.newcastle.edu.au/vital/access/ /manager/Repository/uon:40011 p > .05), though the estimates of effect were consistently negative. Global DNA methylation levels in males were significantly higher than in females (median %5mC: 1.82 vs. 1.03, males and females, respectively, (p < .05)). Conclusion: No association was found between global DNA methylation and child cognition and behavior; however given the small sample, this study should be pooled with other cohorts in future meta-analyses.]]> Fri 15 Jul 2022 10:09:55 AEST ]]>